menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

U.K. startup CellVoyant debuts AI platform that could radically reduce the cost of cell-based therapies such as CAR-T immunotherapy for cancer

6 0
18.12.2025
CellVoyant says its FateView platform can reduce the cost of producing viable cells for therapy by up to 80%

© Fortune